Older patients with acute lymphoblastic leukemia (ALL) have significantly worse outcomes; thus, there is a great need for improved treatments in this group. In this interview, Susan OBrien, MD, of the University of California, Irvine, CA, discusses updated data presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, for the use of inotuzumab ozogamicin in elderly ALL. This included the use of the antibody-drug conjugate in combination with low-intensity chemotherapy (mini-hyper-CVD) for relapsed/refractory ALL, as well as in the frontline setting (NCT01371630). This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Elderly ALL advances: inotuzumab ozogamicin plus mini-hyper-CVD
